Vivre's performance and recovery protocols support the growth-hormone axis, tissue regeneration, and metabolic flexibility. The compounds are administered under physician supervision with biomarker monitoring - including IGF-1, inflammatory markers, and metabolic panel. WADA Prohibited status is disclosed openly for patients in regulated sport.
WADA Prohibited Substances Disclosure
Several compounds in the performance category - including BPC-157 (S0, since 2022), TB-500 (S2), MOTS-c (S2, since 2024), GHRP-2 and GHRP-6 (S2) - are on the World Anti-Doping Agency Prohibited List. If you compete in regulated sport (Olympic-pathway, professional, university), these compounds may result in a sanction.
Vivre's physician consultation will explicitly review your competitive status and adjust protocol accordingly. We will not prescribe WADA-prohibited compounds to athletes in regulated sport without their full informed consent and a documented understanding of testing risk.
The Vivre Approach
Supervised performance medicine. Biomarker-anchored. Not bodybuilding-forum stack design.
Hormone and metabolic baseline first
IGF-1, total/free testosterone, SHBG, thyroid panel, inflammatory markers, lipid panel, fasting insulin. We don't supplement what we haven't measured.
Physician-determined, not patient-designed
Forum-shared stacks have known patient-harm cases. Protocols are designed based on the audit results and adjust based on follow-up biomarkers - not based on what you read about online.
Monitoring beyond intake
IGF-1 and metabolic panel re-testing at protocol checkpoints. Sustained elevation patterns trigger physician adjustment.
Relevant ProtocolsPhysician-supervised stacks
Performance and recovery protocols below. The audit and consultation determine which is appropriate - and whether any protocol is appropriate. For some patients (particularly those with elevated IGF-1 at baseline, or family history of certain cancers), no GH-axis protocol is appropriate; the physician will say so explicitly.
The Peptides in These Protocols
Individual compounds
Patients searching by compound name (CJC-1295, Ipamorelin, BPC-157) often arrive here first. Here are the individual compounds in Vivre's performance and recovery protocols, grouped by what they do. Click any compound for its detailed clinical page, including evidence base, half-life, mechanism, and WADA status.
· when body composition is part of the performance goal
Note: which compounds a given patient receives is determined at consultation, not by self-selection. Vivre's V-Series protocols package these compounds clinically; individual compound pages exist for education and physician reference.
How It Works
01
Biological Audit
Performance-focused audit - IGF-1, hormone panel, metabolic markers, inflammatory markers, lipid panel. Identifies baseline status and contraindications before any protocol discussion.
02
Physician Consultation
Vivre-network physician reviews audit, discusses competitive status (WADA implications), and determines protocol appropriateness. Some audits result in "protocol not indicated" - physician judgment is real.
03
Supervised Protocol
Protocol begins with verified compound supply. IGF-1 and metabolic re-testing at checkpoints. Sustained off-range biomarkers trigger physician adjustment, not patient self-titration.
What Makes This Different
The unsupervised peptide market is substantial and the harm patterns are documented. The distinguishing features of a clinically-credible programme:
Compound verification. Vivre's Double-Gate Protocol verifies every batch. Forum-sourced or research-chemical-grade compounds have no quality guarantee.
IGF-1 monitoring. The GH-axis is potent and IGF-1 elevation is the relevant safety marker. Vivre includes scheduled IGF-1 testing across protocol duration; unsupervised use almost never includes this.
Honest contraindication framing. GH-axis protocols are declinedls for patients with elevated baseline IGF-1, certain cancer histories, or specific risk profiles. This is real clinical judgment, not gatekeeping for show.
WADA disclosure. Athletes in regulated sport are informed explicitly. We do not prescribe to competitive athletes in WADA-tested categories without their full informed consent of testing-risk implications.
Evidence Base · Perform & Recover Compounds
Primary sources · peer-reviewed
Performance and recovery peptides span a wide evidence range - from FDA-approved compounds with full Phase 3 trial data to mechanistically-validated preclinical assets. Vivre cites each at the actual level of evidence that exists.
Tier indicators (gold = human RCT, biochemistry, or genomic; amber = preclinical or investigational) reflect translational distance. Vivre presents human data prominently and flags preclinical evidence explicitly so patients and physicians can weigh it honestly. Click any card for full study breakdown on the compound page.
Common Questions
Are these compounds WADA-prohibited?
Several are - including BPC-157 (S0, since 2022), TB-500 (S2), MOTS-c (S2, since 2024), GHRP-2 and GHRP-6 (S2), AICAR (S4). If you compete in WADA-regulated sport, these protocols may result in sanctions. Vivre will explicitly discuss your competitive status at consultation and adjust accordingly. We will not prescribe WADA-prohibited compounds to athletes in regulated sport without full informed consent.
How is this different from TRT?
TRT (testosterone replacement therapy) addresses testosterone deficiency in patients with confirmed clinical hypogonadism. Vivre's GH-axis protocols (V-G1) address the growth-hormone cascade - a different physiological system. Some patients benefit from both; others from one and not the other; some from neither. The audit and physician consultation determine which, if any, applies. Vivre does not prescribe TRT directly - when TRT is indicated, the physician network handles it under its own clinical framework.
Will my IGF-1 go up too much?
IGF-1 elevation is the relevant safety endpoint for GH-axis protocols. Vivre monitors IGF-1 at baseline, mid-protocol, and end-of-cycle. Sustained elevation above the age-adjusted reference range triggers physician adjustment or protocol pause. This is what physician supervision is for.
What if I'm a competing athlete?
Tell the physician at consultation. The physician will review your competitive category, the testing regimen you're subject to, and the specific compound implications. If a protocol is incompatible with your competitive status, the physician will say so directly and discuss alternatives.
How does this compare to peptides I see on bodybuilding forums?
Forum-sourced peptides have no verification of compound identity, purity, or dose accuracy. The harm patterns from unsupervised use are documented in case reports. Vivre verifies every compound batch, monitors biomarkers across protocol duration, and adjusts based on physician judgment rather than patient self-titration. Different category of product entirely.
How long until I see body composition changes?
Trajectory depends on the protocol, baseline status, training and nutrition adherence, and individual response. For GH-axis protocols, biomarker changes (IGF-1, lipid markers) are typically observable at the first re-testing checkpoint. Body composition changes typically require 12-16 weeks for measurable shift, and the rate varies substantially.
Next Step
Start with the Biological Audit.
The audit provides the data foundation. From there, the physician consultation reviews your competitive status, baseline biomarkers, and determines whether and how a performance protocol fits your case.